Isohelical Sequence Recognising DNA Minor Groove Binders Clinically Active Novel Cancer Drugs for Re

1

• Isohelical Sequence Recognising DNA Minor Groove
  Binders Clinically Active Novel Cancer Drugs for
  Refractory Disease

2
Market Need Drug Resistant Cancers

• Many cancers become resistant to the available
  therapies
• Ovarian cancer 45 become resistant
• equates to a market of 450m
• Hematological cancers 150m
• Later opportunities include
• Colon
• Spleen
• Melanoma
• Spirogens lead product has a 1bn market
  potential

3
Our Solution

• New chemicals that fly under the DNA repair radar
  and so avoid the mechanisms that lead to drug
  resistance in many cancers.
• Highly active (5th most active in National Cancer
  Institute Screens) in a broad range of tumours.

4
Market Context

• Market currently segmented
• Cytotoxic agents mainstay of first line therapy
• But side effects and drug resistance
• Not effective in melanoma, spleen and other
  diseases
• Targeted therapies eg Herceptin, Glevec
• Prolong life, fewer side effects, disease
  specific
• New paradigm is taking hold
• Patients stratified through molecular analysis of
  tumour
• Therapies selcted based on profile
• Spirogens drugs fit into this new paradigm as a
  new class of DNA interactive agent where activity
  is maintained in resistant and hard to treat
  tumours.

5
Commercial Opportunity

• Clinical activity and tolerability have been
  demonstrated
• 3 partial responses and gt1/3rd of patients with
  signs of activity in Phase I
• 12m raised to date which has been invested in
  these drugs
• 4m is being raised to take the lead drug through
  two Phase II trials in ovarian and myeloma/B-CLL
• Plan is to sell the Company/pipeline on
  completion of Phase II
• Comparable deals are in the 100m range
• Target investor return gt 5x over 2-3 years.